Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Klinische Studie zum Treovance Stent-Graft für Patienten mit abdominalen Aortenaneurysmen

10. November 2026 aktualisiert von: Bolton Medical

Eine klinische Phase-II-Studie zur Sicherheit und Leistung des Treovance-Stentgrafts mit Navitel-Einführsystem für Patienten mit infrarenalen Bauchaortenaneurysmen

The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in subjects with Abdominal Aortic Aneurysms (AAA).

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a phase II, multi-center, non-blinded, non-randomized study of treatment with the Treovance Stent-Graft in subjects with abdominal aortic aneurysms. The study will include 150 subjects treated with the Treovance Stent-Graft at a maximum of 30 investigational sites. Upon completion of enrollment of150 subjects, an additional 50 subjects may be treated with the Treovance Stent-Graft at the 30 investigative sites participating in the trial. These additional subjects will follow the same study schedule, and data from these patients may be used to supplement the pivotal trial data. There will be no prospective control group. Subjects diagnosed with infrarenal abdominal aortic aneurysms enrolled in the trial will be treated with the Treovance Stent-Graft with Navitel Delivery System. Pre-procedure baseline data will be gathered, as well as post-procedure assessments prior to hospital discharge and 30 days, 6 months, and 12 months post-implantation. In addition, annual follow-up visits out to 5 years will be conducted. Subjects with fracture(s) confirmed by the Core Lab within the first 5 years will be followed for an additional 5 years, for a total of 10 years post-implantation.

The primary goal of this study is to gather safety and effectiveness data on the Treovance device. A maximum of 150 endovascular subjects will be required to fulfill the U.S. Phase II requirements. The data from this study will be submitted to the FDA and used to support approval in the U.S.

There are two primary objectives, efficacy and safety of the Treovance Stent-Graft in subjects with infrarenal aortic aneurysms:

  • Primary Efficacy will be evaluated by successful aneurysm treatment 12 months post-implant
  • Primary Safety will be assessed by composite major adverse event (MAE) rate at 30-days

Secondary objectives involve assessment of major device-related events and major morbidity.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

158

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35294
        • University of Alabama-Birmingham
    • Arizona
      • Phoenix, Arizona, Vereinigte Staaten, 85006
        • Arizona Heart Institute
    • Connecticut
      • Danbury, Connecticut, Vereinigte Staaten, 06810
        • Danbury Hospital
    • Florida
      • Boca Raton, Florida, Vereinigte Staaten, 33486
        • Lynn Heart and Vascular Institute
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30342
        • Northside Hospital Heart & Vascular Institute
    • Illinois
      • Champaign, Illinois, Vereinigte Staaten, 61820
        • Presence Medical Center -- Christie Clinic
      • Chicago, Illinois, Vereinigte Staaten, 60637
        • University of Chicago
      • Rockford, Illinois, Vereinigte Staaten, 61103
        • Affiliated Surgeons of Rockford Memorial Hospital
    • Iowa
      • Iowa City, Iowa, Vereinigte Staaten, 52242
        • University of Iowa Hospital and Clinic
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Vereinigte Staaten, 02111
        • Tufts University Medical Center
      • Worcester, Massachusetts, Vereinigte Staaten, 01655
        • University of Massachusetts
    • Minnesota
      • Rochester, Minnesota, Vereinigte Staaten, 55905
        • Mayo Clinic
    • New York
      • Albany, New York, Vereinigte Staaten, 12205
        • Community Care (previously Albany Medical Center)
      • Buffalo, New York, Vereinigte Staaten, 14203
        • Buffalo General Medical Center
      • New York, New York, Vereinigte Staaten, 10029
        • Mount Sinai Medical Center
      • Rochester, New York, Vereinigte Staaten, 14623
        • University of Rochester -- Strong Memorial Hospital
      • Stony Brook, New York, Vereinigte Staaten, 11794-8191
        • Stony Brook Medical Center
    • North Carolina
      • Asheville, North Carolina, Vereinigte Staaten, 28801
        • Mission Hospital
      • Greenville, North Carolina, Vereinigte Staaten, 27834
        • East Carolina University / Pitt County Memorial Hospital
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44195
        • Cleveland Clinic Foundation
      • Columbus, Ohio, Vereinigte Staaten, 43210
        • The Ohio State University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19140
        • Temple University School of Medicine
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
        • University of Pittsburgh Medical Center
      • York, Pennsylvania, Vereinigte Staaten, 17403
        • York Hospital
    • Rhode Island
      • Providence, Rhode Island, Vereinigte Staaten, 02905
        • Rhode Island Hospital
    • South Dakota
      • Sioux Falls, South Dakota, Vereinigte Staaten, 57117
        • Sanford University of South Dakota Medical Center
      • Sioux Falls, South Dakota, Vereinigte Staaten, 51108
        • North Central Heart (Avera Heart Hospital)
    • Virginia
      • Norfolk, Virginia, Vereinigte Staaten, 23507
        • Sentara Vascular Specialists

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 85 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Subject must be between the ages of 18 and 85
  2. Subject must be diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without iliac artery involvement, by CT with contrast performed within 4 months of planned implant procedure
  3. Subject must have an infrarenal AAA that i. is > 4.5 cm in diameter for males, or > 4.0 cm in diameter for females, or ii. has increased in diameter by 0.5 cm in the last 6 months
  4. Subject must have i. infrarenal landing neck length of 10 mm or greater and an angle of less than 60 degrees relative to the long axis of the aneurysm (centerline at lowest renal to centerline at bifurcation) and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 17 mm -32 mm, or ii. infrarenal landing neck length of 15 mm or greater and an angle of between 60 and 75 degrees relative to the long axis of the aneurysm and a suprarenal neck angle of less than 45 degrees relative to the infrarenal neck axis and an outside diameter of 16 mm-30 mm
  5. Subject's infrarenal landing neck must meet the vessel size requirements specified in the instructions for use (IFU) for the corresponding devices
  6. Subject must have lowest renal artery at least 9 cm from the aortic bifurcation
  7. Subject must have a distal iliac landing neck with i. an inside diameter of 8 mm - 13 mm and a length of at least 10 mm, or ii. an inside diameter of >13 mm - 20 mm and a length of at least 15 mm
  8. Subject's distal iliac landing neck must meet the vessel size requirements specified for the corresponding devices in the IFU
  9. Subject must have a total treatment length of at least 13 cm
  10. Subject must have a distal aortic diameter above the iliac bifurcation equal to or greater than 70% of the sum of the selected leg graft diameters that will pass through the same
  11. Subject must be willing and able to comply with 1-month, 6-month, and 12-month follow-up visits, as well as annual visits out to 5 years
  12. Subject must have adequate renal function to tolerate required follow-up contrast-enhanced CTs
  13. Subject must have adequate vascular access (e.g., patent iliac or femoral arteries) for introduction of the Navitel Delivery System, which is 18F (6 mm) or 19F (6.3 mm) outer diameter based on size of device used. Alternatively, subject's anatomy is suitable for creation of an iliac conduit.
  14. Subject or Legally Authorized Representative (LAR) must agree to sign Informed Consent Form

Exclusion Criteria:

  1. Subject is pregnant or lactating
  2. Subject has a dissection in abdominal aorta, ruptured aneurysm, or symptomatic aneurysm (as determined by treating physician)
  3. Subject has a patent inferior mesenteric artery that cannot be sacrificed and an occluded or stenotic celiac and/or superior mesenteric artery
  4. Implant procedure as planned does not allow for at least one patent hypogastric artery left intact, unless both are occluded on pre-op imaging
  5. Subject has a lesion that cannot be crossed by a guide wire
  6. Proximal neck cannot increase by more than 10% over 15mm or more than 7% over 10mm; i.e., no trapezoidal necks
  7. Subject has severe untreated coronary artery disease and/or unstable angina, significant areas of myocardium at risk (based on coronary angiogram or radionuclide scans), left ventricular ejection fraction < 20%, or recent diagnosis of Congestive Heart Failure (CHF)
  8. Subject has had a stroke or myocardial infarction within 6 months of the planned treatment date
  9. Subject has chronic obstructive pulmonary disease requiring routine need for oxygen therapy outside the hospital setting (e.g., daily or nightly home use)
  10. Subject has an active systemic infection or is suspected of having an active systemic infection (e.g.,AIDS/HIV, sepsis)
  11. Subject is morbidly obese (more than 100% over the ideal body weight or as defined by institutional standards) or has other clinical conditions that severely compromise or impair x-ray visualization of the aorta
  12. Subject has connective tissue disease (e.g., Marfan's syndrome)
  13. Subject has a mycotic aneurysm
  14. Subject has significant or circumferential calcification or mural thrombus in the proximal aortic neck
  15. Subject has significant or circumferential calcification or mural thrombus in the distal iliac landing zone
  16. Subject has significant or circumferential calcification or mural thrombus within the treatment length, which may adversely impact device patency
  17. Subject has a blood coagulation disorder or bleeding diathesis, the treatment for which cannot be suspended pre- and post-repair
  18. Subject is in acute or chronic renal failure (creatinine > 2.5 mg/dL) unless subject is stable on dialysis
  19. Subject has less than two-year life expectancy as evidenced by factors prohibiting major medical intervention (e.g., presence of malignancy, severe cardiopulmonary disease, etc.)
  20. Subject is participating in another research study, has received investigational study drug within 30 days of planned procedure, or has received an investigational device within one year of planned procedure
  21. Subject is confronted with other medical, social or psychological issues that the investigator believes may interfere with study treatment or follow-up. These reasons must be documented. An example may include adherence to a theological or personal doctrine with aversion or opposition to blood transfusion.
  22. Subject has had a prior AAA repair (endovascular or surgical)
  23. Subject has an untreatable allergy or sensitivity to contrast media, nitinol/nickel, or polyester
  24. Subject has undergone other major surgical or medical intervention within 45 days of the planned procedure or is planning to undergo other major surgical or medical intervention within 45 days post implantation (e.g., Coronary Artery Bypass Graft (CABG), organ transplantation, renal stenting, etc.)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Treovance

Subjects who receive the Treovance stent-graft

Eligible subjects will be implanted with the Treovance Stent-Graft

Andere Namen:
  • Treovance Bauch-Stentgraft mit Navitel-Einführsystem

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Primary Efficacy
Zeitfenster: 12 months

Successful aneurysm treatment which is a composite of the following: Technical success at the conclusion of the procedure; absence of aneurysm enlargement; absence of device-related complications (e.g., fracture, conversion to open surgical repair, etc.)

12 months
Primary Safety
Zeitfenster: 30 days

The primary safety endpoint is composite major adverse event (MAE) rate (including myocardial infarction, stroke, respiratory failure, etc.)

30 days

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Secondary Efficancy Endpoint -- Aneurysm-Related Mortality
Zeitfenster: Annually to 5-years; annually to 10-years (stent-fracture subjects only)

Aneurysm-related mortality at 12 month and annually to 5 years; annually to 10 years for subjects with Core Lab-confirmed fracture(s)

Annually to 5-years; annually to 10-years (stent-fracture subjects only)
Secondary Efficacy Endpoint -- Technical Success
Zeitfenster: 30 days

Technical success at 30 days confirmed by an imaging modality (e.g. CT)

30 days
Secondary Efficacy Endpoint -- Clinical Utility Measures
Zeitfenster: Perioperative/Periprocedural

Clinical utility measures (procedure time, time in the intensive care unit, length of hospital stay)

Perioperative/Periprocedural
Secondary Efficacy Endpoint -- Secondary interventions
Zeitfenster: 30 days, 6 months, annually to 5-years; annually to 10-years (stent-fracture subjects only)

The secondary efficacy endpoint includes the rate of additional procedures performed to correct the original implant

30 days, 6 months, annually to 5-years; annually to 10-years (stent-fracture subjects only)
Secondary Efficacy Endpoint -- Device-Related Events
Zeitfenster: 30 days, 6 months, and annually to 5-years; annually to 10-years (stent-fracture subjects only)

This endpoint includes the rate of events associated with the device.

30 days, 6 months, and annually to 5-years; annually to 10-years (stent-fracture subjects only)
Secondary Safety Endpoint -- Individual Rate for Events included in the composite MAE
Zeitfenster: 30 days, 6 months, annually to 5 years

Secondary safety endpoints will include each individual rate for the adverse events included in the composite MAE at 30 days, 6 months, and annually to 5 years

30 days, 6 months, annually to 5 years
Secondary Safety Endpoint -- Procedure-Related Complications
Zeitfenster: 30 days, 6 months, annually to 5 years

Procedure-related complications at 30 days, 6 months, 12 months, and annually to 5 years.

30 days, 6 months, annually to 5 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Matthew Eagleton, MD, Cleveland Clinic Foundaton

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

23. November 2013

Primärer Abschluss (Tatsächlich)

20. März 2017

Studienabschluss (Tatsächlich)

22. Januar 2026

Studienanmeldedaten

Zuerst eingereicht

6. November 2013

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. Dezember 2013

Zuerst gepostet (Geschätzt)

12. Dezember 2013

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • IP-0008-12

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .